Eli Lilly Other Operating Income or Expenses 2010-2024 | LLY
Eli Lilly annual/quarterly other operating income or expenses history and growth rate from 2010 to 2024. Other operating income or expenses can be defined as the aggregate amount of all operating expenses either too small to report separately or that cannot be standardized into another Zacks field.
- Eli Lilly other operating income or expenses for the quarter ending September 30, 2024 were $-0.082B, a INF% decline year-over-year.
- Eli Lilly other operating income or expenses for the twelve months ending September 30, 2024 were $-0.207B, a 52.74% increase year-over-year.
- Eli Lilly annual other operating income or expenses for 2023 were $-0.068B, a 72.32% decline from 2022.
- Eli Lilly annual other operating income or expenses for 2022 were $-0.245B, a 22.62% decline from 2021.
- Eli Lilly annual other operating income or expenses for 2021 were $-0.316B, a 140.93% increase from 2020.
Eli Lilly Annual Other Operating Income or Expenses
(Millions of US $) |
| 2023 |
$-68 |
| 2022 |
$-245 |
| 2021 |
$-316 |
| 2020 |
$-131 |
| 2019 |
$-576 |
| 2018 |
$-267 |
| 2017 |
$-1,332 |
| 2016 |
$-383 |
| 2015 |
$-368 |
| 2014 |
$-469 |
| 2013 |
$-121 |
| 2012 |
$-281 |
| 2011 |
$-401 |
| 2010 |
$-192 |
| 2009 |
$-693 |
Eli Lilly Quarterly Other Operating Income or Expenses
(Millions of US $) |
| 2024-09-30 |
$-82 |
| 2024-06-30 |
$-154 |
| 2024-03-31 |
|
| 2023-12-31 |
$29 |
| 2023-09-30 |
|
| 2023-06-30 |
$-97 |
| 2023-03-31 |
|
| 2022-12-31 |
$-38 |
| 2022-09-30 |
$-207 |
| 2022-06-30 |
|
| 2022-03-31 |
|
| 2021-12-31 |
$-62 |
| 2021-09-30 |
|
| 2021-06-30 |
$-43 |
| 2021-03-31 |
$-212 |
| 2020-12-31 |
$30 |
| 2020-09-30 |
$-101 |
| 2020-06-30 |
|
| 2020-03-31 |
$-60 |
| 2019-12-31 |
$-439 |
| 2019-09-30 |
|
| 2019-06-30 |
|
| 2019-03-31 |
$-137 |
| 2018-12-31 |
$-193 |
| 2018-09-30 |
$-43 |
| 2018-06-30 |
$26 |
| 2018-03-31 |
$-57 |
| 2017-12-31 |
$-661 |
| 2017-09-30 |
$-407 |
| 2017-06-30 |
$-50 |
| 2017-03-31 |
$-214 |
| 2016-12-31 |
$-148 |
| 2016-09-30 |
$-46 |
| 2016-06-30 |
$-58 |
| 2016-03-31 |
$-131 |
| 2015-12-31 |
$-217 |
| 2015-09-30 |
$-42 |
| 2015-06-30 |
|
| 2015-03-31 |
$-108 |
| 2014-12-31 |
|
| 2014-09-30 |
|
| 2014-06-30 |
|
| 2014-03-31 |
|
| 2013-12-31 |
$-57 |
| 2013-09-30 |
|
| 2013-06-30 |
$-64 |
| 2013-03-31 |
|
| 2012-12-31 |
$-257 |
| 2012-09-30 |
|
| 2012-06-30 |
|
| 2012-03-31 |
$-24 |
| 2011-12-31 |
$-244 |
| 2011-09-30 |
$-25 |
| 2011-06-30 |
$-132 |
| 2011-03-31 |
|
| 2010-12-31 |
|
| 2010-09-30 |
|
| 2010-06-30 |
|
| 2010-03-31 |
|
| 2009-12-31 |
|
| 2009-09-30 |
|
| 2009-06-30 |
|
| 2009-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$692.744B |
$34.124B |
|
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
|
